Poxel commences its Phase 1b trial for NASH drug candidate, PXL065
Category: #health  By Pankaj Singh  Date: 2019-09-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Poxel commences its Phase 1b trial for NASH drug candidate, PXL065

Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by the buildup of fat in the liver mostly with people who drink little or no alcohol. With growing cases of NASH prevailing worldwide, pharmaceutical companies are now focusing on developing new drugs by means for novel clinical trials.

POXEL SA, a biopharmaceutical company that develops advanced treatments for metabolic disorders like non-alcoholic steatohepatitis (NASH), recently made some strides in this field with its Phase 1b randomized, double-blind, placebo-controlled trial in fit candidates to understand the tolerability, pharmacokinetics (PK) and safety of PXL065 (DRX-065).

According to reliable sources, this trial intends to confirm the predicted dose proportionality and relative exposure of the PXL065 (DRX-065), a drug developed to treat patients with noncirrhotic NASH by targeting MPC (mitochondrial pyruvate carrier) inhibition. PXL065 is claimed to have the potential to offer a better therapeutic than 45 mg of Actos®* (pioglitazone).

For the record, pioglitazone was comprehensively researched in NASH with demonstrated effectiveness, but its use is very restricted because of its side effects, like fluid retention and weight gain, which might be linked with the S-stereoisomer.

Commenting on the study, Thomas Kuhn, CEO, Poxel, said that the company’s in-depth knowledge of the cellular energy regulation related to metabolic disorders, like NASH, has immensely assisted it to accelerate the quick development of various pipeline along with two positive clinical programs still in the developing stage for treating this chronic metabolic disease.

He added that according to phase 1 and preclinical results, PXL065 comes out as a promising medicine that shows an improved therapeutic profile when rivaled with pioglitazone for noncirrhotic NASH patients.

Reportedly, Poxel has also made some advances towards treating type 2 diabetes which it disclosed in its recent conference at the 55th Annual Meeting of the EASD (European Association for the Study of Diabetes), conducted in Barcelona, Spain.

The session focused on discussing the medicinal potential of the company’s most promising drug candidate, Imeglimin, a modern treatment focusing on type 2 diabetes in several patient populations, and detailed Phase 3 TIMES 1 outcomes in Japanese patients.

Source Credit: https://www.poxelpharma.com/en_us/news-media/press-releases/detail/127/poxel-initiates-phase-1b-multiple-ascending-dose-mad



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...